Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $615 from $607 and keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $616 from $612 at Morgan Stanley
- Vertex Pharmaceuticals price target raised to $543 from $541 at RBC Capital
- Analyst Maintains Hold on Vertex as Strong CF Franchise Offsets Mixed Q1 Results and Non‑CF Pipeline Uncertainty
- Vertex Pharmaceuticals price target lowered to $436 from $437 at Canaccord
- Vertex Pharmaceuticals price target lowered to $572 from $577 at Bernstein